Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation

被引:17
作者
Hori, A
Kami, M
Kim, SW
Chizuka, A
Kojima, R
Imataki, O
Sakiyama, M
Hamaki, T
Onishi, Y
Usubuchi, N
Kisbi, Y
Murashige, N
Tajima, K
Miyakoshi, S
Heike, Y
Masuo, S
Taniguchi, S
Takaue, Y
机构
[1] Natl Canc Ctr, Stem Cell Transplant Unit, Chuo Ku, Tokyo 1040045, Japan
[2] Toranomon Gen Hosp, Tokyo, Japan
[3] JR Tokyo Gen Hosp, Dept Hematol & Rheumatol, Tokyo, Japan
关键词
reduced-intensity stem cell transplantation bacterial infection; neutropenic fever;
D O I
10.1016/j.bbmt.2003.09.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Little information is available on the clinical characteristics of infectious complications that occur in the early period after reduced-intensity stem cell transplantation (RIST). We retrospectively investigated the clinical features of neutropenic fever and infectious episodes within 30 days after RIST in 76 patients who had received fluoroquinolones as part of their antibacterial prophylaxis. Preparative regimens included cladribine 0.66 mg/kg or fludarabine 180 mg/m(2) plus busulfan 8 mg/kg. All but 1 patient survived 30 days after transplantation, and 75 patients (99%) became neutropenic within a median duration of 9 days. Neutropenic fever was observed in 29 patients (38%), and bacterial infection was confirmed in 15 (20%) of these, including bacteremia (n = 13), bacteremia plus pneumonia (n = 1), and urinary tract infection (n = 1). The causative organisms were gram-positive (n = 9) and gram-negative organisms (n = 7), with a mortality rate of 6%. Neither viral nor fungal infection was documented. Multivariate analysis showed that the presence of neutropenia at the initiation of Preparative regimens was an independent risk factor for subsequent documented bacterial infections (P = .026; 95% confidence interval, 1.25-35.1). We conclude that neutropenic fever and bacteremia remain common complications in RIST. (C) 2004 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 29 条
[1]   Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies [J].
Çelebi, H ;
Akan, H ;
Akçaglayan, E ;
Üstün, C ;
Arat, M .
BONE MARROW TRANSPLANTATION, 2000, 26 (02) :211-214
[2]  
Chizuka A, 2001, BLOOD, V98, p355B
[3]   Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis [J].
Cruciani, M ;
Rampazzo, R ;
Malena, M ;
Lazzarini, L ;
Todeschini, G ;
Messori, A ;
Concia, E .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) :795-805
[4]  
Dykewicz CA, 2000, BIOL BLOOD MARROW TR, V6, P659
[5]   Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients [J].
Dykewicz, CA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) :139-144
[6]   Emergence and dissemination of quinolone-resistant Escherichia coli in the community [J].
Garau, J ;
Xercavins, M ;
Rodríguez-Carballeira, M ;
Gómez-Vera, JR ;
Coll, I ;
Vidal, D ;
Llovet, T ;
Ruíz-Bremón, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2736-2741
[7]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[8]   2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer [J].
Hughes, WT ;
Armstrong, D ;
Bodey, GP ;
Bow, EJ ;
Brown, AE ;
Calandra, T ;
Feld, R ;
Pizzo, PA ;
Rolston, KVI ;
Shenep, JL ;
Young, LS .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :730-751
[9]   Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study [J].
Junghanss, C ;
Marr, KA ;
Carter, RA ;
Sandmaier, BM ;
Maris, MB ;
Maloney, DG ;
Chauncey, T ;
McSweeney, PA ;
Storb, R .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (09) :512-520
[10]   Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation [J].
Kanda, Y ;
Mineishi, S ;
Saito, T ;
Saito, A ;
Yamada, S ;
Ohnishi, M ;
Chizuka, A ;
Niiya, H ;
Suenaga, K ;
Nakai, K ;
Takeuchi, T ;
Makimoto, A ;
Tanosaki, R ;
Kami, M ;
Tanaka, Y ;
Fujita, S ;
Watanabe, T ;
Kobayashi, Y ;
Tobinai, K ;
Takaue, Y .
BONE MARROW TRANSPLANTATION, 2001, 28 (07) :689-692